Drug Profile
Heparinase III
Alternative Names: Extravase; IBT 9302Latest Information Update: 29 Mar 2006
Price :
$50
*
At a glance
- Originator BioMarin Pharmaceutical
- Class Anti-ischaemics; Polysaccharide lyases
- Mechanism of Action Heparan A glucosamide acetyltransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis; Reperfusion injury; Varicose ulcer; Vascular restenosis
Most Recent Events
- 29 Mar 2006 No development reported - Preclinical for Coronary artery restenosis in USA (unspecified route)
- 29 Mar 2006 No development reported - Preclinical for Reperfusion injury in USA (unspecified route)
- 29 Mar 2006 No development reported - Preclinical for Varicose ulcer in USA (unspecified route)